NASDAQ:EKSO - Ekso Bionics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.27 +0.19 (+9.13 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$2.08
Today's Range$2.05 - $2.30
52-Week Range$1.02 - $4.77
Volume812,700 shs
Average Volume612,877 shs
Market Capitalization$128.36 million
P/E Ratio-2.55
Dividend YieldN/A
Beta-0.36
Ekso Bionics logoEkso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company's Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.

Receive EKSO News and Ratings via Email

Sign-up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry General industrial machinery,
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EKSO
CUSIPN/A
Phone510-984-1761

Debt

Debt-to-Equity Ratio0.49
Current Ratio2.17
Quick Ratio1.92

Price-To-Earnings

Trailing P/E Ratio-2.55
Forward P/E Ratio-5.04
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.35 million
Price / Sales18.79
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book6.31

Profitability

EPS (Most Recent Fiscal Year)($0.89)
Net Income$-29,120,000.00
Net Margins-327.12%
Return on Equity-169.75%
Return on Assets-92.06%

Miscellaneous

Employees92
Outstanding Shares60,830,000
Market Cap$128.36 million

Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions

What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work?

Shares of Ekso Bionics reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings Inc (NASDAQ:EKSO) issued its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.02. The business earned $2.97 million during the quarter, compared to analysts' expectations of $3.03 million. Ekso Bionics had a negative return on equity of 169.75% and a negative net margin of 327.12%. View Ekso Bionics' Earnings History.

When is Ekso Bionics' next earnings date?

Ekso Bionics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Ekso Bionics.

Who are some of Ekso Bionics' key competitors?

Who are Ekso Bionics' key executives?

Ekso Bionics' management team includes the folowing people:
  • Mr. Jack Peurach, Pres, CEO & Director (Age 52)
  • Mr. Russell L. DeLonzor, Chief Operating Officer (Age 56)
  • Mr. Maximilian Scheder-Bieschin, Consultant (Age 56)
  • Mr. John F. Glenn, CFO & Sec. (Age 56)
  • Ms. Foon Lim Chwee, Pres of APAC

Has Ekso Bionics been receiving favorable news coverage?

News stories about EKSO stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ekso Bionics earned a news impact score of 0.18 on Accern's scale. They also assigned press coverage about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Ekso Bionics.

Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.18%). Company insiders that own Ekso Bionics stock include Amy Mcbride Wendell, Max Scheder-Bieschin, Russ Angold, Steven Sherman and Thomas Looby. View Institutional Ownership Trends for Ekso Bionics.

Which institutional investors are selling Ekso Bionics stock?

EKSO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for Ekso Bionics.

How do I buy shares of Ekso Bionics?

Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $2.27.

How big of a company is Ekso Bionics?

Ekso Bionics has a market capitalization of $128.36 million and generates $7.35 million in revenue each year. The company earns $-29,120,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Ekso Bionics employs 92 workers across the globe.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected]


MarketBeat Community Rating for Ekso Bionics (NASDAQ EKSO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about Ekso Bionics and other stocks. Vote "Outperform" if you believe EKSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EKSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2018 by MarketBeat.com Staff

Featured Article: Diversification

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel